Last reviewed · How we verify
Vicodin
Vicodin, marketed by Massachusetts General Hospital, is a well-established analgesic in the pain management market. The drug maintains a competitive edge due to its key composition patent, which is set to expire in 2028. The primary risk to Vicodin's market position is the potential increase in generic competition following the patent expiry.
At a glance
| Generic name | Vicodin |
|---|---|
| Also known as | Hydrocodon/Acetaminophen, acetaminophen and hydrocodone |
| Sponsor | Massachusetts General Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Nonopioid Analgesia After Anterior Cruciate Ligament Reconstruction (PHASE2, PHASE3)
- The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery (NA)
- The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery in Gynecologic Oncology (NA)
- A Study on Reducing Opioid Use After Minimally Invasive Ankle Surgery (NA)
- The Efficacy and Safety of Liposomal Bupivacaine for Rhomboid Intercostal Nerve Block in Relieving Postoperative Pain After Video-assisted Thoracoscopic Surgery (NA)
- Post-operative Pain Management in Children With Supracondylar Humerus Fractures (PHASE4)
- Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery (PHASE4)
- SCHF Post-Op Study Between Opioid and Non-Opioid Pain Management (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vicodin CI brief — competitive landscape report
- Vicodin updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI